A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma

PURPOSE: Programmed death-1 (PD-1) inhibitor sintilimab plus bevacizumab has been approved as the first-line treatment for patients with advanced hepatocellular carcinoma (aHCC). However, the clinical benefits of sintilimab plus bevacizumab in a real-world setting in China is insufficiently defined...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Xianghua, Jia, Yingxin, Chen, Hongmei, Luo, Qinli, Zhao, Huakan, Liang, Guanzhong, Chen, Wen, Li, Yongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185451/
https://www.ncbi.nlm.nih.gov/pubmed/37188985
http://dx.doi.org/10.1007/s00432-023-04775-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185451/
https://www.ncbi.nlm.nih.gov/pubmed/37188985
http://dx.doi.org/10.1007/s00432-023-04775-2

Ejemplares similares